[go: up one dir, main page]

EP1622684A4 - COMPOSITIONS AND METHODS FOR SEARCHING FOR NEW COMPOUNDS AND TARGETS - Google Patents

COMPOSITIONS AND METHODS FOR SEARCHING FOR NEW COMPOUNDS AND TARGETS

Info

Publication number
EP1622684A4
EP1622684A4 EP04775923A EP04775923A EP1622684A4 EP 1622684 A4 EP1622684 A4 EP 1622684A4 EP 04775923 A EP04775923 A EP 04775923A EP 04775923 A EP04775923 A EP 04775923A EP 1622684 A4 EP1622684 A4 EP 1622684A4
Authority
EP
European Patent Office
Prior art keywords
targets
searching
compositions
methods
new compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04775923A
Other languages
German (de)
French (fr)
Other versions
EP1622684A2 (en
Inventor
Gary D Glick
Anthony W Opipari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/427,211 external-priority patent/US7572788B2/en
Priority claimed from US10/634,114 external-priority patent/US20040176358A1/en
Priority claimed from US10/795,535 external-priority patent/US7276348B2/en
Application filed by University of Michigan System, University of Michigan Ann Arbor filed Critical University of Michigan System
Publication of EP1622684A2 publication Critical patent/EP1622684A2/en
Publication of EP1622684A4 publication Critical patent/EP1622684A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP04775923A 2003-05-01 2004-04-30 COMPOSITIONS AND METHODS FOR SEARCHING FOR NEW COMPOUNDS AND TARGETS Withdrawn EP1622684A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/427,211 US7572788B2 (en) 1999-04-30 2003-05-01 Compositions and methods relating to novel compounds and targets thereof
US10/427,212 US7144880B2 (en) 1999-04-30 2003-05-01 Compositions relating to novel compounds and targets thereof
US10/634,114 US20040176358A1 (en) 1999-04-30 2003-08-04 Compositions and methods relating to novel compounds and targets thereof
US10/795,535 US7276348B2 (en) 1999-04-30 2004-03-08 Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
PCT/US2004/013455 WO2005004988A2 (en) 2003-05-01 2004-04-30 Compositions and methods relating to novel compounds and targets thereof

Publications (2)

Publication Number Publication Date
EP1622684A2 EP1622684A2 (en) 2006-02-08
EP1622684A4 true EP1622684A4 (en) 2007-07-25

Family

ID=34069318

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04775923A Withdrawn EP1622684A4 (en) 2003-05-01 2004-04-30 COMPOSITIONS AND METHODS FOR SEARCHING FOR NEW COMPOUNDS AND TARGETS

Country Status (6)

Country Link
EP (1) EP1622684A4 (en)
JP (1) JP2007500212A (en)
AU (1) AU2004255153B2 (en)
CA (1) CA2524394C (en)
MX (1) MXPA05011741A (en)
WO (1) WO2005004988A2 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8242109B2 (en) 2007-03-09 2012-08-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
JP2008510734A (en) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド Kinase inhibitor
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2006074358A1 (en) 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7759338B2 (en) 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
JP2010505962A (en) 2006-10-09 2010-02-25 武田薬品工業株式会社 Kinase inhibitor
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016583A1 (en) * 1995-05-18 2001-08-23 Gary D. Glick Therapeutic application of pro-apoptotic benzodiazepines
WO2003015703A2 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016583A1 (en) * 1995-05-18 2001-08-23 Gary D. Glick Therapeutic application of pro-apoptotic benzodiazepines
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
EP1398033A2 (en) * 1999-04-30 2004-03-17 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases, inflammations, neoplasies, viral infections and atherosclerosis
WO2003015703A2 (en) * 2001-08-15 2003-02-27 The Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASTIAN E.D. ET AL: "Casein interference in bovine plasmin assays using a synthetic substrate", JOURNAL OF DAIRY SCIENCE, vol. 74, no. 12, December 1991 (1991-12-01), UNITED STATES, pages 4119 - 4124, XP007906550 *
BLATT N B ET AL: "Benzodiazepine-induced superoxide signals B cell apoptosis: mechanistic insigfht and potential therapeutic utility", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 10, no. 8, October 2002 (2002-10-01), pages 1123 - 1132, XP002422965 *
JOHNSON K.M. ET AL.: "Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase", ACS CHEMICAL BIOLOGY, vol. 1, no. 5, June 2006 (2006-06-01), UNITED STATES, pages 304 - 308, XP007906563 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809323B2 (en) 1999-04-30 2014-08-19 The Regents Of The University Of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
US7994313B2 (en) 2005-06-01 2011-08-09 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US8791104B2 (en) 2005-11-01 2014-07-29 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8088759B2 (en) 2005-11-01 2012-01-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones with therapeutic properties
US8097612B2 (en) 2006-06-09 2012-01-17 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8242109B2 (en) 2007-03-09 2012-08-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US8324258B2 (en) 2007-09-14 2012-12-04 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
US8461153B2 (en) 2007-11-06 2013-06-11 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8759340B2 (en) 2007-11-06 2014-06-24 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8188072B2 (en) 2007-11-06 2012-05-29 The Regents Of The University Of Michigan Benzodiazepinone compounds useful in the treatment of skin conditions
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
US8604023B2 (en) 2009-04-17 2013-12-10 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
US8673897B2 (en) 2009-09-18 2014-03-18 The Regents Of The University Of Michigan Benzodiazepinone compounds and methods of treatment using same
US8815845B2 (en) 2009-11-17 2014-08-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties

Also Published As

Publication number Publication date
EP1622684A2 (en) 2006-02-08
CA2524394C (en) 2011-07-12
MXPA05011741A (en) 2006-05-12
WO2005004988A2 (en) 2005-01-20
CA2524394A1 (en) 2005-01-20
WO2005004988A3 (en) 2006-02-23
AU2004255153A1 (en) 2005-01-20
JP2007500212A (en) 2007-01-11
AU2004255153B2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
EP1622684A4 (en) COMPOSITIONS AND METHODS FOR SEARCHING FOR NEW COMPOUNDS AND TARGETS
EP1765327A4 (en) COMPOUNDS, COMPOSITIONS AND RELATED METHODS
MA27105A1 (en) NEW COMPOUNDS
EP1633336A4 (en) IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS
ATE402934T1 (en) MALONAMIDE DERIVATIVES AS GAMMA SECRETASINE INHIBITORS
EP1653935A4 (en) ANTI-INFLAMMATORY FORMULATIONS
DE602004008136D1 (en) Curable composition
ATE407663T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING AZITHROMYCIN HAVING REDUCED ADVERSE EFFECTS
FI20031301L (en) Esterification method
DK1692242T3 (en) Viscoelastic acid
EP1423122A4 (en) COMPOSITIONS AND METHODS RELATING TO NOVEL BENZODIAZEPINE COMPOUNDS AND TARGETS
EP1778204A4 (en) COMPOSITIONS AND METHODS RELATING TO NEW COMPOUNDS AND TARGETS
DK1587478T3 (en) PHARMACEUTICAL COMPOSITION
DE602004005735D1 (en) PRODUCT EXHIBITION SHELF
IS8309A (en) formulations
EP1951278A4 (en) METHODS AND COMPOSITIONS FOR DEREPRESSION OF IPA-INHIBITED CASPASE
EP1628993A4 (en) RNA INTERFERENCE METHODS AND COMPOSITIONS
DE60322274D1 (en) Time delay measurement
ATE409470T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MALONAMIDE DERIVATIVES FOR REDUCING TABIL PRODUCTION
EP1778219A4 (en) ASCOPHYLLUM COMPOSITIONS AND METHODS
EP1991237A4 (en) CHEMOPROTECTIVE METHODS AND COMPOSITIONS
PT1603550E (en) Pharmaceutical composition comprising 5-methyl-2-2`-(chloro-6`-fluoroanilino)phenylacetic acid
EP1678199A4 (en) METHODS AND COMPOSITIONS FOR THE CONTROL OF EXOTOXINS PRODUCED BY MYCOPLASMA PNEUMONIAE
ITTO20040454A1 (en) FRONT MOTORCYCLE STRUCTURE
FR2864083B1 (en) NOVEL PHENYL BORONIC ACID DERIVATIVES AND METHODS FOR THEIR PREPARATION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 13/00 20060101ALI20060324BHEP

Ipc: A61K 31/00 20060101ALI20060324BHEP

Ipc: A61K 31/55 20060101AFI20060324BHEP

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/5513 20060101AFI20070323BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070626

17Q First examination report despatched

Effective date: 20071109

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20160622BHEP

Ipc: A61K 31/5513 20060101AFI20160622BHEP

Ipc: C12Q 1/42 20060101ALI20160622BHEP

INTG Intention to grant announced

Effective date: 20160708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161119